We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative Analysis

MedXY Editorial Team•Sep 15, 2026•Diabetes & Endocrinology
opioidstype 2 diabetesglucagon-like peptide-1 receptor agonistsgastrointestinal eventsconstipation

Adults with T 2 D using G L P 1 R A include 411,188 patients from Medicare, MarketScan, and Optum Clinformatics, 2016 to 2025. Exposure groups comprise 100,180 oxycodone, 199,601 hydrocodone, and 111,407 tramadol initiators. Outcomes are severe constipation, bowel obstruction, and gastroparesis. Thirty-day weighted risks are 0.51, 0.35, and 0.33 per cent, respectively. R R values are 1.48, 1.55, and 1.05 with 95 percent CI ranges of 1.30 to 1.69, 1.33 to 1.79, and 0.91 to 1.21.

Highlight

• Oxycodone initiation in adults with type 2 diabetes (T2D) on GLP-1 receptor agonists (GLP-1RAs) is associated with higher short-term risks of severe constipation and bowel obstruction compared to hydrocodone and tramadol.
• Hydrocodone and tramadol show comparable gastrointestinal safety profiles in this patient population.
• No significant differences were observed in gastroparesis risk among the opioids studied.
• Careful opioid selection is crucial to minimize gastrointestinal adverse effects in T2D patients receiving GLP-1RA therapy.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World DataFenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.Sep 18, 2026Common Anti-Inflammatory Drugs Linked to Lower Risk of Vision-Threatening Diabetic Retinopathy in Type 2 DiabetesA large retrospective cohort study suggests that cetirizine, ibuprofen, and prednisone use in adults with type 2 diabetes is associated with significantly reduced incidence of diabetic macular edema and proliferative diabetic retinopathy, hSep 15, 2026Linking Female Infertility History to Type 2 Diabetes Risk: Insights from the Nurses’ Health Study IIThis study explores the increased risk of type 2 diabetes among women with a history of infertility, highlighting specific infertility causes and implications independent of BMI.Sep 6, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Sarcopenic Obesity and Type 2 Diabetes Risk: Insights from the UK Biobank Study
This study reveals sarcopenic obesity significantly increases the risk of incident type 2 diabetes, exceeding risks from obesity or sarcopenia alone, highlighting the importance of combined muscle and adiposity assessment in diabetes preven
Sep 6, 2026
Decoding Pancreatic Islet Single-Cell Transcriptomic Diversity Across Type 2 Diabetes SubtypesSingle-cell RNA sequencing of pancreatic islets reveals distinct molecular signatures linked to specific clinical subtypes of type 2 diabetes, highlighting the heterogeneous pathophysiology and providing potential subtype-specific therapeutSep 5, 2026
Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort StudyA large Scandinavian study reveals that ketoacidosis risk during SGLT2 inhibitor therapy in type 2 diabetes varies by patient factors and persists beyond early treatment, highlighting the need for ongoing risk assessment and management straSep 5, 2026